NEORTESBIO, a leading South Korean biotech firm, specializes in developing therapeutic antibodies for retinal diseases, solid tumors, and age-related conditions, with a primary focus on the Angiopoietin-Tie axis a crucial pathway in vasculature regulation.
Our proprietary Tri-VasTrap™, an Ang2-binding and Tie2-activating antibody (ABTAA), stands out by effectively regenerating and normalizing pathologic capillaries, distinguishing itself from conventional VEGF-inhibitors that disrupt vessels.